CJC-1295 DAC — 2 mg

CJC-1295 DAC — 2 mg

CJC-1295 DAC is a synthetic peptide widely studied in research settings for its prolonged interaction with growth hormone–releasing hormone (GHRH) pathways. Researchers examine it for how its drug affinity complex (DAC) modification extends peptide stability, influences sustained growth hormone signaling, and affects downstream physiological markers without broadly activating other pituitary hormone systems.

Key Research Observations on CJC-1295 DAC

Prolonged growth hormone signaling activity
Research literature describes CJC-1295 DAC as a GHRH analog engineered with a DAC modification that increases half-life, enabling sustained stimulation of growth hormone release over extended periods.

Sustained elevation of growth hormone and IGF-1 markers
Studies observe that CJC-1295 DAC is associated with prolonged increases in growth hormone and downstream IGF-1 signaling compared to shorter-acting GHRH analogs.

Investigation of long-acting circadian hormone patterns
Scientific research explores how extended GHRH signaling from CJC-1295 DAC may influence overall growth hormone exposure across circadian cycles rather than discrete pulse timing alone.

Interest in metabolic and tissue signaling research
Academic and preclinical investigations examine CJC-1295 DAC for its downstream effects related to protein synthesis pathways, metabolic regulation, and tissue signaling markers in controlled research models.